Tg Therapeutics (TGTX) Depreciation & Amortization (CF) (2011 - 2026)

Tg Therapeutics' Depreciation & Amortization (CF) history runs 16 years deep, the most recent figure standing at $32000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 300.0% year-over-year to $32000.0 in Q1 2026; TTM through Mar 2026 was $83000.0, a 76.6% increase from a year earlier, with the FY2025 full-year figure at $59000.0, down 13.24% from the prior year.
• Depreciation & Amortization (CF) rose to $32000.0 in Q1 2026 per TGTX's latest filing, from $21000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $78000.0 in Q2 2022 and bottomed at $8000.0 in Q1 2025.
• The 5-year median for Depreciation & Amortization (CF) is $32000.0 (2023), against an average of $39588.2.
• Across the five-year window, Depreciation & Amortization (CF) slumped 84.93% in 2024 and soared 300.0% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $73000.0 in 2022, then tumbled by 47.95% to $38000.0 in 2023, then plunged by 76.32% to $9000.0 in 2024, then jumped by 133.33% to $21000.0 in 2025, then surged by 52.38% to $32000.0 in 2026.
• Per Business Quant, the three latest TGTX Depreciation & Amortization (CF) figures stand at $32000.0 (Q1 2026), $21000.0 (Q4 2025), and $17000.0 (Q3 2025).